Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 34-year-old man is evaluated in the outpatient psychiatric clinic for a routine follow-up. He has a history of treatment-resistant schizophrenia and was started on clozapine 6 weeks ago after failing trials of risperidone and olanzapine. His psychiatric symptoms have significantly improved, and he reports no auditory hallucinations for the past two weeks. He currently smokes one pack of cigarettes daily. He feels well and denies fever, chills, sore throat, or fatigue. His vital signs are within normal limits. Baseline laboratory studies prior to initiating clozapine showed a total leukocyte count of 7,200/μL7,200/\mu\text{L} and an absolute neutrophil count (ANC) of 4,500/μL4,500/\mu\text{L}. Today, his total leukocyte count is 3,800/μL3,800/\mu\text{L} and his ANC is 1,300/μL1,300/\mu\text{L}. The patient is not of an ethnicity typically associated with benign ethnic neutropenia. Based on the current monitoring parameters, which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Continue clozapine therapy and increase the frequency of absolute neutrophil count monitoring to three times weeklyAnswer
  2. B
    Interrupt clozapine therapy, monitor the absolute neutrophil count daily, and resume once the count is >1,500/μL>1,500/\mu\text{L}
  3. C
    Discontinue clozapine therapy permanently and transition to haloperidol
  4. D
    Prescribe filgrastim to stimulate neutrophil production while continuing the current clozapine dose
  5. E
    Advise immediate smoking cessation to reduce cytochrome P450 1A2 induction and improve bone marrow function

Answer

The most appropriate next step is to continue the clozapine therapy and increase the frequency of absolute neutrophil count (ANC) monitoring to three times weekly.
The patient has developed mild neutropenia (defined as an ANC between 1,000 and 1,499/μL) while taking clozapine. According to the FDA Clozapine REMS guidelines for patients in the general population (without benign ethnic neutropenia), the appropriate management for mild neutropenia is to continue clozapine treatment but increase the frequency of ANC monitoring to three times weekly. This heightened surveillance must continue until the ANC recovers to the normal range (≥1,500/μL).

Step-by-Step Solution

1
Evaluate the patient's current Absolute Neutrophil Count (ANC) against the established baseline and standard reference ranges.
The current ANC is 1,300/μL, which is a decrease from the baseline of 4,500/μL but remains above 1,000/μL.
Identifying the exact tier of neutropenia is required to apply the Clozapine Risk Evaluation and Mitigation Strategy (REMS) protocol.
2
Categorize the severity of the neutropenia according to Clozapine REMS guidelines for the general population.
An ANC of 1,000 to 1,499/μL is categorized as Mild Neutropenia.
Management pathways strictly depend on whether neutropenia is mild, moderate, or severe.
3
Determine the guideline-directed intervention for mild neutropenia in an asymptomatic patient.
The guidelines mandate continuing clozapine treatment but increasing the frequency of ANC monitoring to three times weekly until the ANC returns to ≥1,500/μL.
This protocol balances the critical need for continued psychiatric stabilization against the risk of progressing to severe agranulocytosis.

Key Concept

Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines for monitoring absolute neutrophil count (ANC) and managing treatment-induced neutropenia.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic